Gilead Sciences, Inc. (GILD)
The company now
Gilead Sciences, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Foster City, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $29 billion and a profit of $8.5 billion (its filed statements).
From its filings and filed figures; the desk's account of it is not written yet.
Where the revenue comes from
fiscal 2025, as filedRevenue by product, fiscal 2025
| Product | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| HIV Products Biktarvy | $14.33B | $13.42B | 48.7% |
| Oncology Product | $3.24B | $3.29B | 11.0% |
| Cell Therapy Products Total Cell Therapy Product Sales | $1.84B | $1.97B | 6.2% |
| HIV Products Genvoya | $1.50B | $1.76B | 5.1% |
| Trodelvy | $1.40B | $1.31B | 4.7% |
| Liver Disease Products Sofosbuvir Velpatasvir | $1.27B | $1.60B | 4.3% |
| HIV Products Odefsey | $1.17B | $1.29B | 4.0% |
| Liver Disease Products Vemlidy | $1.07B | $959M | 3.6% |
| Veklury | $911M | $1.80B | 3.1% |
| Liver Disease Products Other Liver Disease | $874M | $467M | 3.0% |
| Other Products Total Other Product Sales | $799M | $889M | 2.7% |
| Royalty Contract and Other | $527M | $144M | 1.8% |
| Other Products Am Bisome | $509M | $533M | 1.7% |
Revenue by region, fiscal 2025
| Region | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| United States | $20.88B | $20.59B | 70.9% |
| Europe | $5.06B | $4.63B | 17.2% |
| Rest of World | $3.50B | $3.53B | 11.9% |
As tagged in its annual report (Form 10-K, filed Feb 24, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.
The desk's written account of this company, its Past, Present and Future, is not on file yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
The desk has not written this company's report yet.